December deal flurry rolls on with Genentech-Caris cancer collab worth up to $1.1B

{
  "signal_id": "33ef234d-42b3-4a93-8c6d-c0d9def7a41a",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2025-12-16T11:00:25+00:00",
  "company": {
    "name": "Caris Life Sciences",
    "domain": "carislifesciences.com"
  },
  "data": {
    "url": "https://www.fiercebiotech.com/biotech/deal-making-flurry-continues-genentech-offers-caris-11b-biobucks-cancer-collab",
    "title": "December deal flurry rolls on with Genentech-Caris cancer collab worth up to $1.1B",
    "excerpt": "December deal flurry rolls on with genentech-caris cancer collab worth up to $1.1B.\n\nA flurry of dealmaking hasn't let up as 2025 comes to a close, with Roche subsidiary Genentech getting in on the action and crafting a multi-year cancer collaboration with Caris Life Sciences.\n\nGenentech is teaming up with AI-focused Caris' therapeutic research arm - dubbed Caris Discovery - in an effort to discover new oncology targets in solid tumor tissue, according to a Dec. 16 release.\n\nUnder the terms of the deal, Caris could collect $25 million in upfront and near-term payments, with Genentech also offering up to $1.1 billion in possible R&D, commercial and sales milestones, plus potential royalties.\n\nIn exchange, \"techbio\" company Caris will work to identify and validate new cancer targets, with the pair's ultimate goal to develop a first-in-class precision medicine. The Texas-based company touts an AI-enabled multimodal database and tissue-based discovery engine used to create diagnostics for early detection, monitoring, therapy selection and drug development.\n\nThe cancer testing company also gleans knowledge from its repository of almost 500,000 solid tumor samples, plus matched molecular and clinical data, to offer target discovery capabilities to partners, such as Merck KGaA and Moderna.\n\nThe deal follows in the boot steps of numerous other biopharmas inking deals, with Sanofi...",
    "product": "first-in-class precision medicine",
    "summary": "Caris Life Sciences, Ltd. is developing first-in-class precision medicine.",
    "category": "is_developing",
    "found_at": "2025-12-16T11:00:25Z",
    "planning": false,
    "image_url": "https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-886921014.jpg?VersionId=xf48pXo0M_1JSkM0ysEGReyRja8p19E5",
    "confidence": 0.9069,
    "product_data": {
      "full_text": "first-in-class precision medicine",
      "fuzzy_match": true
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2025-12-16T11:00:25Z",
    "article_sentence": "In exchange, \"techbio\" company Caris will work to identify and validate new cancer targets, with the pair's ultimate goal to develop a first-in-class precision medicine."
  }
}

curl https://signals.autobound.ai/v1/signals/33ef234d-42b3-4a93-8c6d-c0d9def7a41a \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"carislifesciences.com","limit":20}'